SGEN - シアトル・ジェネティクス (Seattle Genetics Inc.) シアトル・ジェネティクス

 SGENのチャート


 SGENの企業情報

symbol SGEN
会社名 Seattle Genetics Inc (シアトル・ジェネティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 シアトル・ジェネティクス(Seattle Genetics Inc.)は主に癌に対するモノクローナル抗体に基づく治療薬の開発・商品化に従事するバイオテクノロジー会社。同社の候補薬剤であるADCETRIS(brentuximab vedotin)は米国食品医薬品局(FDA)より二つの適応症における承認を受けた。一つは、自家幹細胞移植(ASCT)の障害が発生した後、またはASCT候補者ではない患者に対する二つ以上の前マルチエージェントの化学療法レジメンの障害が発生した後に、ホジキンリンパ腫患者に対する治療である。もう一つは、前マルチエージェントの化学療法レジメンの障害が発生した後に、全身未分化大細胞リンパ腫(ALCL)の患者に対する治療である。ADCETRISは抗体医薬品複合体(ADC)であり、抗CD30モノクローナル抗体により構成され、同社の技術を利用して、微小管破壊剤であるモノメチルアウリスタチンE(MMAE)にプロテアーゼ切断可能なリンカーで接続している。   シアトル・ジェネティクスは、米国のバイオテクノロジ―企業。抗体を使用した癌の治療薬の開発と商品化に従事。同社は抗体が持つ標的化能力を利用し、殺細胞剤を直接がん細胞に届けるようにデザインされた技術抗体薬物複合体(ADC)の開発に特化している。武田薬品工業株式会社と提携し、ADCETRISの共同開発を行う。   Seagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union.
本社所在地 21823 30th Drive SE Bothell WA 98021 USA
代表者氏名 Clay B. Siegall Clay B. Siegall
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 425-527-4000
設立年月日 35612
市場名 NASDAQ National Market System
ipoyear 2001年
従業員数 1100人
url www.seattlegenetics.com
nasdaq_url https://www.nasdaq.com/symbol/sgen
adr_tso
EBITDA EBITDA(百万ドル) -173.43500
終値(lastsale) 77.17
時価総額(marketcap) 12253938665.94
時価総額 時価総額(百万ドル) 11401.23
売上高 売上高(百万ドル) 575.65900
企業価値(EV) 企業価値(EV)(百万ドル) 10953.253
当期純利益 当期純利益(百万ドル) -44.62200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Seattle Genetics Inc. revenues increased 43% to $310.8M. Net loss decreased 70% to $35.4M. Revenues reflect Net product sales increase of 51% to $217.8M Collaboration and license agreement reve increase of 31% to $56.7M Royalty revenues increase of 23% to $36.2M. Lower net loss reflects Investment and other income (loss) net increase from $2.2M to $88.7M (income).

 SGENのテクニカル分析


 SGENのニュース

   Seagen Inc (SGEN) President & CEO Clay B Siegall Sold $4.8 million of Shares  2021/08/07 17:15:10 GuruFocus
Related Stocks: SGEN ,
   Seagen Inc (SGEN): Price Now Near $160.19; Daily Chart Shows An Uptrend on 100 Day Basis  2021/08/06 15:15:34 ETF Daily News
This is the 2nd day in a row sgen has seen its price head down. The post Seagen Inc (SGEN): Price Now Near $160.19; Daily Chart Shows An Uptrend on 100 Day Basis appeared first on ETF Daily News .
   numbers crunched for you before earnings results Seagen (NASDAQ:SGEN)  2021/07/29 18:20:00 Stock Market Daily
Earnings results for Seagen , Analyst Opinion on Seagen , Earnings and Valuation of (NASDAQ:SGEN), Stock market Insights & financial analysis, Best stock to invest, Investment Idea, The post numbers crunched for you before earnings results Seagen (NASDAQ:SGEN) appeared first on .
   Global Antibody Production Services Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Roche, Johnson & Johnson, Merck, Novartis, AbbVie, Amgen, Pfizer, Bayer, Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Biogen, AstraZeneca, Sanofi, Alexion Pharmaceuticals, Seattle Genetics  2021/07/24 01:29:29 Jumbo News
The report on Global Antibody Production Services Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic []
   EFG Asset Management (Americas) Corp. Buys Generac Holdings Inc, Tradeweb Markets Inc, XPO ...  2021/07/23 16:38:12 GuruFocus
Related Stocks: SGEN , IGF , PFF , VCYT , XNCR , BPMC , GNRC , TW , XPO , REET , INCY , ARGX , IAU , MKTX , VRSK , CVS , FGEN , NOBL ,
   Seagen to Host Conference Call and Webcast Discussion of Second Quarter 2021 Financial Results on July 29, 2021  2021/07/08 12:00:00 Business Wire
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its second quarter 2021 financial results on Thursday, July 29, 2021 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast discussion of the results and provide a business update. Access to the event can be obtained as follows: Thursday, July 29, 2021 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time Telephone 844-763-8274 (U.S
   Seagen: Substantially More Growth For This Stalwart  2021/06/20 14:14:05 Seeking Alpha
   Antibody Drug Conjugate Market 2021 (impact of COVID-19) Trend, Future Scope, Growth, Demand, Industry Outlook by top key players Mersana Therapeutics, Seattle Genetics/Takeda, Oxford BioTherapeutics, ImmunoGen, Heidelberg Pharma,  2021/06/15 12:50:35 OpenPR
A report was released recently that sheds lots of light on the Antibody Drug Conjugate Industry. The report covers an overview of the industry along with a detailed explanation that provides a lot of insight. The report also analyzes the
   SpringWorks teams up with Seagen to evaluate nirogacestat combo in multiple myeloma  2021/06/07 10:44:18 Seeking Alpha
   Anti-body Coupled T Receptor Therapy Market - Size, Trends, and Analysis 2020-2027 | Seattle Genetics, Unum Therapeutics  2021/06/02 05:32:57 OpenPR
The Latest research study released by CMI "Global Anti-body Coupled T Receptor Therapy Market" with 360+ pages of analysis on business Strategy taken up by key and emerging industry players and delivers know how of the current market development, landscape,
   Seagen Recommends Rejection Of 'Mini-Tender' Offer from TRC Capital Investment Corporation  2021/03/05 13:00:00 Business Wire
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced that it has been notified of an unsolicited “mini-tender” offer dated February 22, 2021, made by TRC Capital Investment Corporation, an Ontario, Canada corporation, to purchase up to 1,000,000 shares of Seagen's common stock. According to TRC, its “mini-tender” offer price of $151.00 per share was approximately 4.28% below the closing price of Seagen's common stock on February 19, 2021, the last trading day prior to the
   Seagen to Present at the Cowen 41st Annual Healthcare Conference  2021/02/24 13:00:00 Business Wire
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that management will participate in a fireside chat at the Cowen 41st Annual Healthcare Conference on Monday, March 1, 2021 at 2:40 p.m. Eastern Time. The presentation will be webcast live and available for replay from Seagen’s website at www.seagen.com in the Investors section. About Seagen Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a mea
   Seagen and Astellas Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer  2021/02/18 13:00:00 Business Wire
BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced completion of submissions for two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for PADCEV® (enfortumab vedotin-ejfv). One submission, based on the phase 3 EV-301 trial, seeks to convert PADCEV’s accelerated approval to regular approval. The second submission, based on th
   Seagen and Astellas Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy  2021/02/12 19:15:00 Business Wire
BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced results from the second cohort (cohort 2) of patients in the pivotal phase 2 single-arm EV-201 trial. In the trial, 52 percent of patients who received PADCEV® (enfortumab vedotin-ejfv) had an objective response (95 percent Confidence Interval [CI]: 40.8, 62.4) and the median duration of response was 10.9 months (95 percent
   Seagen and Astellas Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer  2021/02/12 19:15:00 Business Wire
BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced primary results from the phase 3 EV-301 trial comparing PADCEV® (enfortumab vedotin-ejfv) to chemotherapy in adult patients with locally advanced or metastatic urothelial cancer who were previously treated with platinum-based chemotherapy and a PD-1/L1 inhibitor. At the time of pre-specified interim analysis, patients who r

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 シアトル・ジェネティクス SGEN Seattle Genetics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)